No-Touch spray could ease shingles nerve pain
NCT ID NCT07599800
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a lidocaine spray (APC101) for people with postherpetic neuralgia, a painful nerve condition after shingles. The spray delivers pain relief without touching the sensitive skin. About 333 adults will use the spray or a placebo to see if it reduces pain over 24 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lidocaine spray 5% solution
- What this could lead to
- If it works, this could provide a convenient, gentle way to manage nerve pain after shingles without touching the painful skin.
- What could go wrong
- This is an early-to-mid stage trial, so the spray may not prove more effective than a placebo. Also, lidocaine can cause skin irritation or allergic reactions in some people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHN - POST-HERPETIC NEURITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Suncoast Clinical Research
Florida City, Florida, 34652, United States
-
University of Sunshine Cost
Brisbane, Queensland, 4117, Australia